Tempest Therapeutics
TPST
16 hedge funds and large institutions have $5.36M invested in Tempest Therapeutics in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 16 → 16 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.6% less ownership
Funds ownership: 30.17% → 29.57% (-0.6%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
40% less capital inflows, than outflows
Capital inflows: $100K | Capital outflows: $165K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$95.4K |
| 2 |
Tower Research Capital (TRC)
New York
|
+$3.71K |
| 3 |
Franklin Resources
San Mateo,
California
|
+$771 |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$178 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$59 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ikarian Capital
Dallas,
Texas
|
-$132K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.1K |
| 3 |
Millennium Management
New York
|
-$6.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.84K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$4.57K |
TPST Hedge Fund Activity: Q3 2022 in Review
16 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2022, worth a combined $5.36M — down 20% from $6.67M a quarter earlier.
Fund positioning in TPST was balanced in Q3 2022: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 5 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $95.4K. The largest seller was Ikarian Capital, exiting entirely with an estimated $132K sold.
- 16 institutional investors held Tempest Therapeutics (TPST) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $5.36M of Tempest Therapeutics stock for Q3 2022, down 20% quarter-over-quarter.
- 1 fund opened new Tempest Therapeutics positions in Q3 2022 and 1 closed out, a net change of 0 holders.
- The largest Tempest Therapeutics buyer in Q3 2022 was Geode Capital Management, an estimated $95.4K added.
- The largest Tempest Therapeutics seller in Q3 2022 was Ikarian Capital, an estimated $132K sold.
Based on aggregated 13F filings for Q3 2022.